Skip to main content
. Author manuscript; available in PMC: 2020 Nov 1.
Published in final edited form as: Psychopharmacology (Berl). 2019 May 28;236(11):3183–3195. doi: 10.1007/s00213-019-05274-4

Fig. 5.

Fig. 5

Vortioxetine does not increase the proliferation of or inhibit the anti-proliferative effects of androgen deprivation on prostate cancer cells in vitro. a Analysis of the concentration-dependent effects of vortioxetine on the growth of LNCaP, PC-3, and DU 145 prostate cancer cell lines over 48 h using the SRB assay indicate that vortioxetine did not promote cancer cell growth. Results are expressed as percent growth compared to vehicle controls (mean ± SEM; n=3). b Enzalutamide inhibited the growth of androgen-dependent LNCaP prostate cancer cells over 48 h in a concentration-dependent manner, evaluated using the SRB assay (n=4). C) Vortioxetine (1 μM) had no effect on the enzalutamide-dependent growth inhibition of LNCaP prostate cancer cells (n=3).